Research Summary - Nanotechnology

In cooperation with Prof. Giovanni Tosi, University of Modena and Reggio Emilia

Our group’s research interests are focused on the translation of nanotechnology-tools focusing on nanoparticles into the medical research area as Nanomedicine tools for next generation medical practice.

The key Nanomedicine areas of interest where we have developed expertise are:

  1. CNS drug delivery: Using polymeric (PLGA) NPs shown to cross the blood brain barrier

  1. Nanocharacterization and Safety: Cellular and tissue safety and toxicity

  1. Theranostics and Preclinical applications: Therapeutics based on nanotechnology focusing on the areas of Autism and Alzheimer’s disease.

Our expertise has been developed as part of a long standing interdisciplinary collaborative work where we have developed assessment models for the investigation of the interactions between nanoparticles and biologically relevant cull culture and animal models.

Current projects:

CNS delivery of Curcumin

CNS delivery of metal attenuating compounds and trace metals

RESEARCH experience:


RUOZI B, BELLETTI D, PEDERZOLI F, MASONI M, KELLER J, BALLESTRAZZI A, VANDELLI MA, TOSI G, GRABRUCKER AM. Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates. Int J Pharm 2017; 526 (1-2): 413-424

BELLETTI D, GRABRUCKER AM, PEDERZOLI F, MENRATH I, CAPELLO V, VANDELLIi MA, FORNI F, TOSI G, RUOZI B: Exploiting the versatility of Cholesterol Nanoparticles formulation. Int J Pharm 2016; 511 (1): 331-340.

GRABRUCKER AM, RUOZI B, BELLETTI D, PEDERZOLI F, FORNI F, VANDELLI MA, TOSI G: Nanoparticle transport across the BBB. Tissue Barriers, 2016; 4 (1): e1153568.

Chhabra R, Ruozi B, Vilella A, Belletti D, Mangus K, Pfaender S, Sarowar T, Boeckers TM, Zoli M, Forni F, Vandelli MA, Tosi G, Grabrucker AM: Application of polymeric nanoparticles for CNS targeted zinc delivery in vivo. CNS & Neurological Disorders-Drug Targets 2015; 14 (8): 1041-53.

Chhabra R, Tosi G, Grabrucker AM: Emerging use of nanotechnology in the treatment of neurological disorders. Current Pharmaceutical Design 2015; 21 (22): 3111-30.

Chhabra R, Grabrucker AM, Veratti P, Belletti D, Boeckers TM, Vandelli MA, Forni F, Tosi G, Ruozi B: Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release. Int J Pharm 2014; 471 (1-2): 349-357.

Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, BoeckerS TM, Forni F, Zoli M: Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. Journal of Controlled Release 2014; 174: 195-201.

Tosi G, Vilella A, Schmeisser MJ, BoeckerS TM, Ruozi B, Vandelli MA, Forni F, Zoli M, Grabrucker AM: Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport Journal of Controlled Release 2014; 177C: 96-107.

Grabrucker AM, Garner CC, Boeckers TM, Bondioli L, Ruozi B, Forni F, Vandelli MA, Tosi G: Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: in vitro evidences. Plos One 2011, 6 (3): e17851.


Tosi G, Ruozi B, Vilella A, Grabrucker AM, Belletti D, Vandelli MA, Boeckers TM, Forni F, Zoli M, Sharma A, Muresanu DF, Sharma HS. Nanomedicine in neurodegenerative disorders: Understanding the journey. NSTI: Advanced Materials - TechConnect Briefs 2015, 3 pp. 25 - 28.

GRABRUCKER AM, CHHABRA R, BELLETTI D, FORNI F, VANDELLI MA, RUOZI B, TOSI G. Nanoparticles as Blood-Brain Barrier Permeable CNS Targeted Drug Delivery Systems. Top Med Chem. 2014, 10: 71-90